Switch to optionsXpress for advanced derivatives trading & earn 50 commission-free trades.
Advertisement
SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Sunshine Biopharma Inc. (SBFM)

SBFM RSS Feed
Add SBFM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BooDog, Gordon Buffett
Search This Board:
Last Post: 3/27/2015 3:55:48 PM - Followers: 167 - Board type: Free - Posts Today: 1








 



 

 


"The Future Of Medicine"
 

 




 
Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 





 

Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 
 


Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697




 



Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.


Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options




 





 

 



 

 
 
Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.







Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective. 







 
Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).




The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.
 






Sunshine Biopharma Drug Pipeline

Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug







 



http://sunshinebiopharma.com/investor/press-releases/
 
November 19, 2014
 
 
SUNSHINE BIOPHARMA SIGNS AGREEMENT WITH LONZA TO MANUFACTURE ITS LEAD ANTI-CANCER COMPOUND, Adva-27a
 
 
Montreal, Quebec, Canada -- (Marketwire) -- Sunshine Biopharma Inc. (OTCQB: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a.  Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine’s Adva-27a.  Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization.  Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
 
“We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.  “We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts.”
 
“We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound”, said James Leresche, Ph.D., Head of Lonza’s Chemical Development Services. “This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”
 
About Lonza
 
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
 
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
 
 
 

 
 
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
 
About Adva-27a
 
Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).  Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.  The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
 
Safe Harbor Forward-Looking Statements
 
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
 
For Additional Information:
 
Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Joshua Ciarrocca: jciarrocca@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
www.renmarkfinacial.com
 
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 
Lonza Media Contacts:
Colleen Floreck, +1 201 316 9290, colleen.floreck@lonza.com
Constance Ward, +41 61 316 8840, constance.ward@lonza.com
 
Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.

Nansha China
http://www.lonza.com/about-lonza/company-profile/locations-worldwide/nansha-china.aspx

Visp Switzerland
http://www.lonza.com/about-lonza/company-profile/locations-worldwide/visp-switzerland.aspx




SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals
 
 

 
We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

 
Intellectual Property

 
We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
 
 
Advanomics

http://www.canada-companies-info.com/advanomics-corporationcorporation-advanomics-65q2
Advanomics Corporation, the Parent Company of Sunshine Biopharma
 

Head Office:

Advanomics Corporation

2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Canada

Tel: 514-764-9698
Fax: 514-764-9699
info@advanomics.com

Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Joshua Ciarrocca: jciarrocca@renmarkfinancial.com
Tel.: (416) 644-2020 or (514) 939-3989
www.renmarkfinacial.com
 
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 

Product Pipeline

Our product pipeline is comprised of the following anti-tumor compounds:

Adva-27a

Difluoro-Etoposide™
Entering Phase I later this year (Lead Compound)

 

Adva-R46

RNAi Anti-Cancer drug candidate
Soon to enter animal studies phase

 

Adva-33c

Difluoro-Carboplatin™
Currently in preclinical phase



 







SBFM Share Structure
 

From otcmarkets.com and SEC filings
The number of shares of the registrant’s only class of common stock issued and outstanding as of November 10, 2014, was 68,911,041 shares.
 

Authorized Shares 200,000,000 a/o Dec 31, 2011

31.5 million held by Steve Slilaty, CEO




SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

http://corporatestock.com




Sunshine Biopharma Inc.
2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Canada
Tel: 514-764-9698
Fax: 514-764-9699

http://sunshinebiopharma.com
info@sunshinebiopharma.com


 

 



 


 

 












































































 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SBFM
Current Price
Volume:
Bid Ask Day's Range
Wiki
SBFM News: Annual Report (10-k) 03/11/2015 04:28:45 PM
SBFM News: Current Report Filing (8-k) 02/24/2015 12:44:31 PM
SBFM News: Statement of Changes in Beneficial Ownership (4) 01/22/2015 11:49:09 AM
SBFM News: Current Report Filing (8-k) 11/19/2014 04:01:04 PM
SBFM News: Quarterly Report (10-q) 11/12/2014 07:01:12 AM
PostSubject
#18925  Sticky Note All they are saying is NOISE. Clueless BooDog 02/10/15 06:05:42 AM
#11692  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 10/09/13 10:52:01 AM
#19228   Sure you have the geography right? lol BooDog 03/27/15 03:55:48 PM
#19227   Dont put nothing in here,your going to lose Cash Monster 03/26/15 10:06:13 PM
#19226   He tell me buy,put many money put money in bombaykid 03/26/15 09:56:27 PM
#19225   I think your manager is smoking some good Cash Monster 03/26/15 09:50:53 PM
#19224   My supervise lonza in india tell me buy bombaykid 03/26/15 09:39:13 PM
#19223   that is not true,i work for lonza in bombaykid 03/26/15 09:30:00 PM
#19222   Hospital will never close,sbfm is dead,ceo took everyones Jimmythegreek 03/26/15 08:48:53 PM
#19221   Called the hospital today and spoke to gerald Jimmythegreek 03/26/15 08:14:42 PM
#19220   Do you want to join us in a Jimmythegreek 03/26/15 08:07:55 PM
#19219   Cry me a river . Call the police I clearsudden 03/26/15 07:58:58 PM
#19218   Re,fraudster slilaty should be in jail Jimmythegreek 03/26/15 07:57:53 PM
#19217   The Jewish is one of Canada's top hospital Kalinn 03/26/15 02:36:52 PM
#19216   yes and thats part of the game you clearsudden 03/26/15 01:07:14 PM
#19215   Investors here lost it all,including yourself,you lost over Cash Monster 03/25/15 11:30:24 PM
#19214   Everyone here knows about the turd slilaty crapmaster Cash Monster 03/25/15 11:26:16 PM
#19213   That's a lie You can only make so much clearsudden 03/25/15 11:12:02 PM
#19212   Thejewish general craped all over agreement and flushed Cash Monster 03/25/15 11:08:10 PM
#19211   The jewish is under major renovations That hospital is clearsudden 03/25/15 10:19:45 PM
#19210   This turd crap slilaty made investors sleep on Cash Monster 03/25/15 07:21:48 PM
#19209   All crap agreements get flushed down the toilet bowl Cash Monster 03/25/15 06:21:51 PM
#19208   I heard the Hospitals are merging in montreal, reginaliberta 03/25/15 02:08:26 PM
#19207   could be transferring shares to the new joe Kalinn 03/24/15 11:35:13 PM
#19206   Adva is in india in 1.2 billion toilet bowls Cash Monster 03/24/15 10:25:19 PM
#19205   More news to flush down the toilet bowl Cash Monster 03/24/15 06:09:31 PM
#19204   Who the hell is buying, can't be an reginaliberta 03/24/15 11:01:15 AM
#19203   ANGEL !!! They just strapped rocket boosters Gordon Buffett 03/24/15 11:00:07 AM
#19202   I'm afraid news will send this into sub reginaliberta 03/24/15 10:59:13 AM
#19201   TELL HIM TO TAKE OUT THE REAL NEWS Angel21stCentury 03/24/15 10:53:43 AM
#19200   THIS BIG FAT GARBAGE CAN BETTER FILE IND! Angel21stCentury 03/24/15 10:49:35 AM
#19199   http://money.cnn.com/news/newsfeeds/articles/globenewswire/10126043.htm Angel21stCentury 03/24/15 10:43:37 AM
#19198   NEWS,NEWS,WE GOT NEWS Sunshine Biopharma Announces Issuance of Angel21stCentury 03/24/15 10:41:18 AM
#19197   More shares being STOLEN! Gordon Buffett 03/24/15 10:24:35 AM
#19196   Adva-27a has excellent pharmacokinetics profile in rats..... Gordon Buffett 03/24/15 10:22:23 AM
#19195   THE DIRTY SCUMBAG BETTER HAVE SOME GOOD NEWS,AND Angel21stCentury 03/23/15 11:43:05 PM
#19194   He has no news,he has nothing,he scammed everyone. Cash Monster 03/23/15 11:13:50 PM
#19193   Its nowhere the ceo is a well know Cash Monster 03/23/15 11:10:26 PM
#19192   YOU BETTER TAKE OUT THE NEWS YOU DIRTY Angel21stCentury 03/23/15 11:02:51 PM
#19191   WHERE IS ADVA-27A,WHERE IS ADVANOMICS??? Angel21stCentury 03/23/15 11:01:31 PM
#19190   WHERE IS THE CURE TO CANCER????? Angel21stCentury 03/23/15 10:59:00 PM
#19189   WHERE ARE CLINICAL TRIALS YOU DIRTY SCUMBAG STEVE N.SLILATY??? Angel21stCentury 03/23/15 10:58:01 PM
#19188   WHERE IS LONZA WITH GMP MANUFACTURING??? Angel21stCentury 03/23/15 10:56:25 PM
#19187   WHERE IS PRODUCTION OF ADVA-27A??? Angel21stCentury 03/23/15 10:55:06 PM
#19186   WHERE ARE ANIMAL STUDIES??? Angel21stCentury 03/23/15 10:54:03 PM
#19185   WHERE IS GARMEN LABS AQUISITION???? Angel21stCentury 03/23/15 10:52:57 PM
#19184   WHERE IS BETA PHARMA??? Angel21stCentury 03/23/15 10:51:43 PM
#19183   WHERE IS IND?????? Angel21stCentury 03/23/15 10:50:55 PM
#19182   He brought a billion dollar company strait to Cash Monster 03/23/15 08:57:11 PM
#19181   Slilaty the turd brought, genomics one,gen-id lab services,alertbc,s2 Cash Monster 03/23/15 08:55:06 PM
#19180   Licensor advanomics swallowed all funds from sbfm shareholders,advanomics Jimmythegreek 03/23/15 08:40:48 PM
#19179   Yaaasuuu re,PM me if you want to sue Jimmythegreek 03/23/15 08:32:37 PM
PostSubject